甲氨蝶呤用于银屑病关节炎。
Methotrexate in psoriatic arthritis.
作者信息
Singh Y N, Verma K K, Kumar A, Malaviya A N
机构信息
Department of Medicine, All India Institute of Medical Sciences, New Delhi.
出版信息
J Assoc Physicians India. 1994 Nov;42(11):860-2.
Thirty three patients with psoriatic arthritis were treated with starting dose of 7.5 mg of methotrexate orally, every week for a period of 6 months to 7 years (mean 2.2 years) along with non-steroidal anti-inflammatory agents. The dose of methotrexate during the course of therapy ranged 5 to 15 mg/week (mean 7.8 mg). There was complete to partial remission in arthritis and psoriatic skin lesions in 94% (31) patients. No response was noticed in 2 patients. Regular monitoring of haematological, renal and liver function tests was done. No significant side effects of the drug, requiring discontinuation of the therapy, were seen during the treatment. Methotrexate can be used early in the course of psoriatic arthritis with good results.
33例银屑病关节炎患者口服甲氨蝶呤起始剂量为7.5mg，每周1次，疗程6个月至7年（平均2.2年），同时服用非甾体抗炎药。治疗过程中甲氨蝶呤剂量为5至15mg/周（平均7.8mg）。94%（31例）患者的关节炎和银屑病皮肤病变实现了完全或部分缓解。2例患者无反应。定期进行血液学、肾功能和肝功能检查。治疗期间未观察到需要停药的药物显著副作用。甲氨蝶呤可在银屑病关节炎病程早期使用，效果良好。
Zotero 插件